Pieris Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, PIRS, Pieris Pharmaceuticals Inc, priceseries

Pieris Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
2.94
Close
2.93
High
3.00
Low
2.89
Previous Close
2.94
Daily Price Gain
-0.01
YTD High
4.08
YTD High Date
Jan 4, 2022
YTD Low
2.85
YTD Low Date
Feb 24, 2022
YTD Price Change
-0.98
YTD Gain
-25.06%
52 Week High
6.15
52 Week High Date
Sep 24, 2021
52 Week Low
1.70
52 Week Low Date
May 5, 2021
52 Week Price Change
0.52
52 Week Gain
21.58%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
1.46
Jan 19. 2017
1.80
11 Trading Days
23.08%
Link
LONG
Jan 24. 2017
1.91
Feb 8. 2017
2.05
11 Trading Days
7.40%
Link
LONG
Mar 1. 2017
2.07
Mar 20. 2017
2.58
13 Trading Days
24.85%
Link
LONG
May 23. 2017
4.02
Jun 6. 2017
4.52
9 Trading Days
12.37%
Link
LONG
Jun 29. 2017
4.94
Jul 13. 2017
5.44
9 Trading Days
10.11%
Link
LONG
Sep 27. 2017
5.42
Oct 12. 2017
6.01
11 Trading Days
10.91%
Link
LONG
Nov 16. 2017
5.78
Nov 29. 2017
6.09
8 Trading Days
5.37%
Link
LONG
Dec 21. 2017
6.26
Jan 16. 2018
7.08
15 Trading Days
13.13%
Link
LONG
May 9. 2019
3.19
May 23. 2019
3.47
10 Trading Days
8.89%
Link
LONG
Jul 26. 2019
4.75
Aug 5. 2019
5.01
6 Trading Days
5.58%
Link
LONG
Sep 9. 2019
4.78
Sep 24. 2019
5.21
11 Trading Days
9.05%
Link
LONG
Oct 31. 2019
3.31
Nov 12. 2019
3.50
8 Trading Days
5.82%
Link
LONG
May 20. 2020
3.05
Jun 4. 2020
3.33
10 Trading Days
9.27%
Link
LONG
May 25. 2021
3.76
May 26. 2021
4.42
1 Trading Days
17.69%
Link
LONG
Aug 17. 2021
3.83
Sep 20. 2021
5.53
23 Trading Days
44.49%
Link
Company Information
Stock Symbol
PIRS
Exchange
NasdaqCM
Company URL
http://www.pieris.com
Company Phone
857-246-8998
CEO
Stephen S. Yoder
Headquarters
Massachusetts
Business Address
255 STATE STREET, 9TH FLOOR, BOSTON, MA 02109
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001583648
About

Pieris Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. It offers technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. The company was founded in 2001 and is headquartered in Freising-Weihenstephan, Germany.

Description

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. The company develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on the development of three drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; and PRS-343, a bispecific protein for oncology diseases. The company has collaboration agreements with Allergan, Inc.; Daiichi Sankyo Company Limited; Sanofi Group; Cadila Healthcare Limited (Zydus Cadila); Strides Arcolab Limited; and F.HoffmannLa Roche Ltd. It also has a strategic alliance with Servier Forge for the co-development of immuno-oncology. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading